[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.241.199. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
April 2014

Isotretinoin and Pregnancy PreventionDo We Need to Take a Long, Hard Look at Ourselves?

Author Affiliations
  • 1Summit Medical Group, Berkeley Heights, New Jersey
JAMA Dermatol. 2014;150(4):361-362. doi:10.1001/jamadermatol.2013.6973

It’s no news that isotretinoin, the most effective treatment for severe or recalcitrant acne, is a potent teratogen. From its release as Accutane by Hoffman-LaRoche in 1982, isotretinoin had been classified as a pregnancy category X drug, defined as a drug with positive evidence of human fetal risk, where the risks involved in use of the drug in pregnant women clearly outweigh potential benefits. Risk management at the time of initial approval was limited to labeling, which described the risk of teratogenicity in the package insert and the patient information brochure. In relatively short order, it was clear that such labeling was not enough to reduce the risk of fetal exposure to isotretinoin.

First Page Preview View Large
First page PDF preview
First page PDF preview
×